medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2021, Número 1

<< Anterior

Rev Biomed 2021; 32 (1)


Prevención de la sarcopenia en pacientes con enfermedad de Parkinson: Revisión descriptiva desde la medicina preventiva

Rodríguez-López M, Sánchez-Tuyú JL, Méndez-Domínguez N

Idioma: Español
Referencias bibliográficas: 70
Paginas: 55-65
Archivo PDF: 333.04 Kb.


RESUMEN

La enfermedad de Parkinson ocupa el segundo lugar de las enfermedades neurodegenerativas más comunes en el mundo. La sarcopenia se caracteriza por dinapenia y en los adultos mayores con diagnóstico de enfermedad de Parkinson acelera su progresión. El objetivo de la presente revisión es describir el estado sarcopénico y la importancia de su prevención en los adultos mayores con enfermedad de Parkinson, así como ofrecer una revisión de las medidas de prevención primaria, secundaria y terciaria pertinentes para su abordaje. Si bien el deterioro y la gravedad de la enfermedad de Parkinson se relacionan directamente con el estado sarcopénico del paciente mediante el abordaje multidisciplinario, la medicina preventiva puede favorecer la calidad de vida de los pacientes mediante medidas de promoción, diagnóstico oportuno, tratamiento farmacológico y no farmacológico y limitación de la progresión de la sarcopenia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Martínez FR, Gasca SC, Sánchez FÁ, Obeso JA. Actualización en la enfermedad de Parkinson. Rev Med Clin Condes. 2016;27(3):363-79. doi: 10.1016/j. rmclc.2016.06.010

  2. Rotondo J, Toro M, Bolívar M, Seijas ME, Carrillo C. Dolor en la enfermedad de Parkinson. Una mirada a un aspecto poco conocido de esta patología. Revista de la Sociedad Española del Dolor. 2019 Jun;26(3):184-98. doi: 10.20986/resed.2019.3733/2019

  3. Navarro RC, Rodríguez VM, Cervantes AA. Terapias de infusión en la enfermedad de Parkinson avanzada. Rev Mex Neuroci. 2019;20(1):3-13. doi: 10.24875/RMN. M19000018

  4. T, Mao X, Park H. Poly (ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease. Mov Disord Clin Pract. 2019;6(3):199. doi: 10.1002/ mdc3.12727

  5. Xiao Y, Lau JC, Hemachandra D, Gilmore G, Khan A, Peters TM. Image guidance in deep brain stimulation surgery to treat Parkinson’s disease: a comprehensive review. IEEE Trans Biomed Eng. 2020. doi: 10.1109/ TBME.2020.3006765

  6. Diagnóstico y tratamiento de la Enfermedad de Parkinson inicial y avanzada en el tercer nivel de atención, México: Secretaría de Salud, 2010.

  7. Chávez DV, Infante SH, Serralde AE. Sarcopenia y funcionalidad en el adulto mayor hospitalizado. Nutr Hosp. 2015;31(4):1660-66. doi: 10.3305/ nh.2015.31.4.8502

  8. Yazar T, Yazar HO, Zayimoğlu E, Çankaya S. Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease. Neurol Sci. 2018;39(8):1415-21. doi: 10.1007/s10072-018-3439-6

  9. Phu S, Vogrin S, Zanker J, Hassan EB, Al Saedi A, Duque G. Agreement between initial and revised European Working Group on Sarcopenia in older people definitions. Journal of the American Medical Directors Association. 2019 Mar 1;20(3):382-3. doi: 10.1016/j. jamda.2018.11.026

  10. Vetrano DL, Pisciotta MS, Laudisio A, Lo Monaco MR, Onder G, Brandi V, et al. Sarcopenia in Parkinson Disease: Comparison of Different Criteria and Association With Disease Severity. J Am Med Dir Assoc. 2018;19(6):523- 27. doi: 10.1016/j.jamda.2017.12.005

  11. Lai CH, Chen HC, Liou TH, Li W, Chen SC. Exercise Interventions for Individuals with Neurological Disorders: A Systematic Review of Systematic Reviews. Am J Phys Med Rehabil. 2019; 98(10):921-30. doi: 10.1097/PHM.0000000000001247

  12. Rendón-Rodríguez R, Osuna-Padilla IA. El papel de la nutrición en la prevención y manejo de la sarcopenia en el adulto mayor. Nutr Clin Med. 2018;12(1):23-36. doi: 10.7400/NCM.2018.12.1.5060

  13. Castillo-Rodríguez A, Onetti-Onetti W, Sousa Mendes R, Chinchilla-Minguet JL. Relationship between Leg Strength and Balance and Lean Body Mass. Benefits for Active Aging. Sustainability. 2020 Jan;12(6):2380. doi:10.3390/su12062380

  14. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294-305. doi: 10.1159/000356760

  15. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB. Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. J Am Med Dir Assoc. 2011; 12(4):249-56. doi: 10.1016/jamda.2011.01.003

  16. Duan Y, Zheng C, Zhong Y, Song B, Yan Z, Kong X, Deng J, Li F, Yin Y. Beta-hydroxy beta-methyl butyrate decreases muscle protein degradation via increased Akt/FoxO3a signaling and mitochondrial biogenesis in weanling piglets after lipopolysaccharide challenge. Food & function. 2019;10(8):5152-65. doi: 10.1007/ s00441-019-03021-x

  17. Beasley JM, Shikany JM, Thomson CA. The role of dietary protein intake in the prevention of sarcopenia of aging. Nutr Clin Pract. 2013;28(6):684-90. doi: 10.1177/0884533613507607

  18. Drummond MJ, Addison O, Brunker L, Hopkins PN, McClain DA, LaStayo PC, et al. Downregulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of physically inactive, frail older women: a 822 cross-sectional comparison. J Gerontol A Biol Sci Med Sci. 2014; 69(8):1040-48. doi: 10.1093/gerona/glu004

  19. Joseph AM, Adhihetty PJ, Buford TW. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell. 2012;11(5):801-9. doi: 10.1111/j.1474-9726.2012. 00844.x

  20. Fry CS, Drummond MJ, Glynn EL, Dickinson JM, Gundermann DM, Timmerman KL, et al. Skeletal muscle autophagy and protein breakdown following resistance exercise are similar in younger and older adults. J Gerontol A Biol Sci Med Sci. 2013; 68:599– 607. doi: 10.1093/gerona/gls209

  21. Vetrano DL, Landi F, Volpato S, Corsonello A, Meloni E, Bernabei R, et al. Association of sarcopenia with shortand long-term mortality in older adults admitted to acute care wards: Results from the crime study. J Gerontol Ser A Biol Sci Med Sci 2014;69:1154-61. doi: 10.1093/gerona/glu034

  22. Peball M, Mahlknecht P, Werkmann M, Marini K, Murr F, Herzmann H, Willeit P. Prevalence and associated factors of sarcopenia and frailty in Parkinson’s disease: a cross-sectional study. Gerontology 2019;65(3):216-28. doi:10.1159/000492572

  23. Ozer FF, Akın S, Gultekin M, Zararsız GE. Sarcopenia, dynapenia, and body composition in Parkinson’s disease: are they good predictors of disability? A case–control study. Neurological Sciences 2020;41(2):313-20. doi: 10.1007/s10072-019-04073-1

  24. Bian A, Ma Y, Zhou X, Guo Y, Wang W, Zhang Y, et al. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet Disord. 2020; 21:14. doi: 10.1186/ s12891-020-03236-y

  25. Basualto-Alarcón C, Varela D, Duran J, Maass R, Estrada M. Sarcopenia and Androgens: A Link between Pathology and Treatment. Front Endocrinol (Lausanne). 2014; 5:217. doi: 10.3389/fendo.2014.00217

  26. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies, J Diabetes Metab Disord. 2017; 16:21. doi: 10.1186/s40200-017-0302-x

  27. García AA, García BF. La medicina preventiva en la atención primaria de salud. Rev. Haban Cienc Med. 2012;11(2):308-16.

  28. Valenzuela RER, Ponce JA, Morales-Figueroa GG, Muro KA, Carreón VR, Alemán-Mateo H. Insufficient amounts and inadequate distribution of dietary protein intake in apparently healthy older adults in a developing country: implications for dietary strategies to prevent sarcopenia. Clin Interv Aging. 2013; 8:1143-48. doi: 10.2147/CIA.S49810

  29. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017; 28(6):1817-33. doi: 10.1007/s00198-017-3980-9.

  30. Naseeb MA, Volpe SL. Protein and exercise in the prevention of sarcopenia and aging. Nutr Res. 2017; 40:1-20. doi: 10.1016/j.nutres.2017.01.001

  31. Granic A, Dismore L, Hurst C, Robinson SM, Sayer AA. Myoprotective Whole Foods, Muscle Health and Sarcopenia: A Systematic Review of Observational and Intervention Studies in Older Adults. Nutrients. 2020;12(8):2257. doi: 10.3390/nu12082257.

  32. Wirth R, Dziewas R, Jäger M, Warnecke T, Smoliner C, Stingel K, et al. Clinical Nutrition in Neurology – Part of the Ongoing S3-Guideline Project Clinical Nutrition. Aktuel Ernahrungsmed. 2013;38(4): e49-e89. doi: 10.1055/s-0033-1343317 (Alemán)

  33. Curhan SG, Halpin C, Wang M, Eavey RD, Curhan GC. Prospective Study of Dietary Patterns and Hearing Threshold Elevation. American Journal of Epidemiology. 2020 Mar 2;189(3):204-14. doi: 10.1093/aje/kwz223

  34. Alcalay RN, Gu Y, Mejia SH, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Mov Disord. 2012;27(6):771-4. doi: 10.1002/mds.24918

  35. Robinson SM, Reginster JY, Rizzoli R, Shaw SC, Kanis JA, Bautmans I, et al. Does nutrition play a role in the prevention and management of sarcopenia? Clin Nutr. 2018;37(4):1121-32. doi: 10.1016/j.clnu.2017.08.016

  36. Wu H, Xia Y, Jiang J, Du H, Guo X, Liu X, et al. Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2015;61(2):168- 75. doi:10.1016/j. archger.2015.06.020

  37. Reynaldo CLE, González GY, Rodríguez LR. Adherencia a programas de rehabilitación física como tratamiento efectivo en enfermedades neurodegenerativas. Revista científica especializada en Cultura Física y Deportes. 2019;17(43):129-40.

  38. Nascimento CM, Ingles M, Salvador PA, Cominetti MR, Gomez CMC, Viña J. Sarcopenia, frailty and their prevention by exercise. Free Radical Biology and Medicine. 2019; 132:42-9. doi: 10.1016/j. freeradbiomed.2018.08.035

  39. Xu Z, Tan Z, Zhang Q, Gui Q, Yang Y. Clinical Effectiveness of Protein and Amino Acid Supplementation on Building Muscle Mass in Elderly People : A Meta- Analysis. PloS One. 2014; 9(9). doi: 10.1371/journal. pone.0109141

  40. Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. J Nutr Health Aging. 2016; 14:15–28. doi: 10.1007/s12603-016-0704- 3

  41. Tello-Rodríguez, Alarcón, RD, Vizcarra-Escobar D. Salud mental en el adulto mayor: trastornos neurocognitivos mayores, afectivos y del sueño. Rev Peru Med Exp Salud Publica. 2016;33(2):342-50. doi: 10.17843/rpmesp.2016.332.2211

  42. Naranjo JEG, Alfonso MA, Delgado AIC, Chacón LMM, Rodriguez A. Trastornos del sueño en pacientes con enfermedad de Parkinson. Rev Cubana Neurol Neurocir. 2020;10(1). doi: 10.3390/bs9010006

  43. Ospina GN. Trastornos del sueño y dolor en la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019; 35:63-8. doi: 10.22379/24224022251

  44. Li SX, Lam SP, Zhang J, Yu MW, Chan JW, Liu Y, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016; 21:114-20. doi: 10.1016/j.sleep.2015.12.020

  45. McCarter SJ, Boswell CL, St Louis EK, Dueffert LG, Slocumb N, Boeve BF, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14(3):237-42. doi: 10.1016/j.sleep.2012.09.018

  46. Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, et al. Treatment of insomnia in Parkinson’s disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708-14. doi: 10.1002/ mds.23168

  47. Kuhlman GD, Flanigan JL, Sperling SA, Barrett MJ. Predictors of health-related quality of life in Parkinson’s disease. Parkinsonism & related disorders. 2019 Aug 1;65:86-90. doi: 10.1016/j.parkreldis.2019.05.009

  48. Rodríguez-Violante M, Zerón-Martínez R, Cervantes- Arriaga A. Complejo sintomático no motor de la enfermedad de Parkinson. Neurología, Neurocirugía y Psiquiatría. 2017;45(2):51-60.

  49. Taekema DG, Gussekloo J, Maier AB, Westendorp RG, Craen AJ. Handgrip streght as a predictor of functional, psychological and social health A prospective populationbase study among the oldest old. Age Ageing. 2010; 39:331-7. doi: 10.1093/ageing/afq022

  50. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care. 2010;13(1):1-7. doi: 10.1097/MCO.0b013e328333c1c1

  51. Bauer JM, Morley JE. Body composition measurements in older adults. Current Opinion in Clinical Nutrition & Metabolic Care. 2020 Jan 1;23(1):1-3. doi: 10.1038/ s41430-019-0508-8

  52. Bioelectrical impedance analysis in body composition measurement: National

  53. de Freitas MM, de Oliveira VL, Grassi T, Valduga K, Miller ME, Schuchmann RA, Souza KL, de Azevedo MJ, Viana LV, de Paula TP. Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus. Experimental Gerontology. 2020 Apr 1;132:110835. doi: 10.1016/j. exger.2020.110835

  54. Tosato M, Marzetti E, Cesari M, Savera G, Miller RR, Bernabei R, Landi F, Calvani R. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging clinical and experimental research. 2017 Feb 1;29(1):19-27. doi:0.1007/s40520-016-0717-0

  55. Hirschfeld HP, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporosis International. 2017 Oct 1;28(10):2781-90. doi: 10.1007/ s00198-017-4151-8

  56. Coelho-Junior HJ, Picca A, Calvani R, Uchida MC, Marzetti E. If my muscle could talk: Myokines as a biomarker of frailty. Experimental gerontology. 2019 Nov 1;127:110715. doi: 10.1016/j.exger.2019.110715

  57. McGrath RP, Kraemer WJ, Al Snih S, Peterson MD. Handgrip strength and health in aging adults. Sports medicine. 2018 Sep 1;48(9):1993-2000. 10.1007/ s40279-018-0952-y

  58. Haynes EM, Neubauer NA, Cornett KM, O’Connor BP, Jones GR, Jakobi JM. Age and sex-related decline of muscle strength across the adult lifespan: a scoping review of aggregated data. Applied Physiology, Nutrition, and Metabolism. 2020;45(11):1185-96. doi:10.1139/ apnm-2020-0081

  59. Adrion C, Weiss B, Paul N, Berger E, Busse R, Marschall U, Caumanns J, Rosseau S, Mansmann U, Spies C. Enhanced Recovery after Intensive Care (ERIC): study protocol for a German stepped wedge cluster randomised controlled trial to evaluate the effectiveness of a critical care telehealth program on process quality and functional outcomes. BMJ open. 2020 Sep 1;10(9):e036096. 10.1136/bmjopen-2019-036096

  60. Portegijs E, Karavirta L, Saajanaho M, Rantalainen T, Rantanen T. Assessing physical performance and physical activity in large population-based aging studies: home-based assessments or visits to the research center?. BMC public health. 2019 Dec 1;19(1):1570. doi: 10.1186/s12889-019-7869-8

  61. Soto-Varela A, Rossi-Izquierdo M, del-Río-Valeiras M, Faraldo-García A, Vaamonde-Sánchez-Andrade I, Lirola-Delgado A, Santos-Pérez S. Modified Timed Up and Go Test for Tendency to Fall and Balance Assessment in Elderly Patients With Gait Instability. Frontiers in Neurology. 2020 Jun 12;11:543. doi: 10.3389/fneur.2020.00543

  62. Morley J. Treatment of sarcopenia: the road to the future. J Cachexia Sarcopenia Muscle. 2018;9(7):1196-99. doi: 10.1002/jcsm.12386

  63. Dhillon R, Hasni S. Pathogenesis and Management of Sarcopenia. Clin Geriatr Med. 2017;33(1):17-26. doi: 10.1016/j.cger.2016.08.002

  64. Marras C, Chaudhuri KR, Titova N, Mestre TA. Therapy of Parkinson’s Disease Subtypes. Neurotherapeutics. 2020 Aug 4. doi: 10.1007/s13311-020-00894-7

  65. Xiao Y, Lau JC, Hemachandra D, Gilmore G, Khan A, Peters TM. Image guidance in deep brain stimulation surgery to treat Parkinson’s disease: a comprehensive review. IEEE Trans Biomed Eng. 2020 Jul 2;PP. doi: 10.1109/TBME.2020.3006765

  66. Murach KA, Mobley CB, Zdunek CJ, Frick KK, Jones SR, McCarthy JJ, Peterson CA, Dungan CM. Muscle memory: myonuclear accretion, maintenance, morphology, and miRNA levels with training and detraining in adult mice. Journal of cachexia, sarcopenia and muscle. 2020 Sep 2. doi:10.1002/jcsm.12617

  67. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12(6):403-9. doi: 10.1016/j.jamda.2011.04.014

  68. Yoshimura Y, Wakabayashi H, Yamada M, Kim H, Harada A, Arai H. Interventions for Treating Sarcopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. J Am Med Dir Assoc. 2017;18(6):553. doi: 10.1016/j.jamda.2017.03.019

  69. Csoti I, Dresel C, Hauptmann B, Müller T, Redecker C, Warnecke T, et al. Nutritional aspects in Parkinson’s disease: disease risk, dietary therapy and treatment of digestive tract dysfunction. Fortschr Neurol Psychiatr. 2018; 86(S01):S34-S42. doi: 10.1055/a-0681- 6700 (Alemán)

  70. Aguilar-Parra JM, Gallego J, Fernández-Campoy JM, Pérez-Gallardo ER, Trigueros R, et al. Influencia de programas de actividad física en la calidad del sueño de personas mayores de 55 años. RPD. 2015;24(2):289-95.




2020     |     www.medigraphic.com